Abstract
Cell Therapeutics (CTI) has licensed exclusive marketing and co-development rights in North, Central and South America to Chroma Therapeutics’ late-stage cancer drug, tosedostat, which will be initially developed for acute myeloid leukaemia, myelodysplastic syndrome and multiple myeloma. The agreement will boost CTI’s late-stage development pipeline as it attempts to gain US regulatory approval for its lead oncology drug, Pixuvri™ (pixantrone dimaleate).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
